
CHMP Recommends Subcutaneous RYBREVANT® for Advanced EGFR-Mutated NSCLC Treatment
Janssen-Cilag International NV, a subsidiary of Johnson & Johnson, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the Subcutaneous European Medicines Agency (EMA) has issued…